Last reviewed · How we verify

NCT05360992

Pulmonary Embolism: Mechanism and Therapeutic Innovation

Completed Last updated 4 May 2022
What this trial tests

trial in Pulmonary Embolism in 1,200 participants. Completed in 13 October 2021.

Timeline
1 January 2017
Primary endpoint
13 October 2021
13 October 2021

Quick facts

Lead sponsorChina National Center for Cardiovascular Diseases
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,200
Start date1 January 2017
Primary completion13 October 2021
Estimated completion13 October 2021

Conditions studied

Sponsor

China National Center for Cardiovascular Diseases — full company profile →

Who can join

18 and older, any sex, with Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the pathogenesis, therapy and outcome of pulmonary embolism (PE) and chronic thromboembolic pulmonary hypertension (CTEPH).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Chronic Thromboembolic Pulmonary Hypertension in Females: Clinical Features and Survival.
    Wu Y, Hu S, Yan XX, Peng FH, et al · · 2022 · cited 3× · PMID 36135453 · DOI 10.3390/jcdd9090308

Verify or expand the search:

Other recruiting trials for Pulmonary Embolism

Currently open trials in the same condition.

Other China National Center for Cardiovascular Diseases trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05360992.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing